Updated on 1 August 2016
Singapore: As per the recent report in the Economic Times, Bangladeshi drugmaker Beacon Pharma has become the first generic drug company in the world to produce copycat versions of Gilead < SNG-QTS>s newly launched Epclusa (Sofosbuvir + Velpatasvir) -- a drug used to treat all types of Hepatitis C infections. As per sources, the drug Epclusa has a cure rate of 95 per cent.
The report further said that the drug has a very high price tag of $75,000, however, Beacon, will look at pricing the drug 10x less than that of its originator. "Our brand will be known as SOFOSVEL, this will be the first generic launch of this drug," said, Mr Monjul Alam, senior vice-president, Beacon Pharma, to ET.
The USFDA had approved this combination as a path breaking therapy to cure even the harshest genotype of patients suffering from the disease. The report further mentioned that Beacon is hoping to reach out to patients from 45 countries across the world, including India, through its patient support program which allows patients to directly purchase the drug through the manufacturer.
Beacon manufactures more than 200 generic drugs and 65 oncology products. In each year, Beacon is introducing more than 15-20 Hi-Tech new products. By the virtue of strong R & D team, Beacon has introduced a number of global first generic, which makes Beacon popular to the pharmaceutical arena of the world.
WHO estimates that approximately 700 000 people die each year from hepatitis C-related liver diseases. Globally, between 130-150 million people globally have chronic hepatitis C infection. Hepatitis C is a liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.